Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.2536
−$0.0092 · -3.50%
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Previous close
$0.2536
−$0.0092 · -3.50%
After-hours
$0.247
−$0.0066 · -2.60%
Oct 7, 7:37 PM ET
Regular session · ET · Market data may be delayed.
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Day range
Current $0.2536
52-week range
Current $0.2536
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
43
Fair Value
Sentiment
53
Mixed
Risk
63
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Day range
Current $0.2536
52-week range
Current $0.2536
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 7.14M USD | 5.82M USD | 3.71M USD | 3.23M USD | — |
| Selling, general, and administrative | 4.48M USD | 6.73M USD | 928K USD | 577K USD | 943.93K USD |
| Operating expenses | −11.63M USD | 12.57M USD | 4.68M USD | 3.86M USD | 943.93K USD |
| Interest income | 142K USD | 1K USD | 153K USD | 114K USD | 6.37K USD |
| Interest expense | 13K USD | 52K USD | 9K USD | 85K USD | — |
| Depreciation and amortization | 14K USD | 25K USD | 45K USD | 57K USD | — |
| Operating income | 11.63M USD | −12.57M USD | −4.68M USD | −3.86M USD | −943.93K USD |
| Net income | −11.91M USD | −16.44M USD | −4.94M USD | −3.22M USD | −755.22K USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 29, 2026 | 1:10 | — | — |
Stock split | Jul 29, 2025 | 1:15 | — | — |
Stock split | Nov 29, 2024 | 1:9 | — | — |
Effective May 29, 2026
1:10
Effective Jul 29, 2025
1:15
Effective Nov 29, 2024
1:9
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
